Contrasts in resonance: from linear to macrocyclic

Authors

Keywords:

contrast media, gadolinium, magnetic resonance spectroscopy

Abstract

Introduction: the use of magnetic resonance contrast media is a necessity. In order to obtain a more effective image, the most ideal contrast should be used to minimize adverse reactions and deposition in tissues and target organs. Due to the repeated use of these contrasts in patients with oncologic follow-up of brain tumors, contrast deposits have been observed in the brain.
Objective: to study the characteristics of gadolinium-based contrast media and their use in magnetic resonance imaging.
Methods: a documentary review was carried out, theoretical methods were used for the theoretical references of the subject, the interpretation of the documentary review and the progression of the information in the articles.
Results: the toxicity of gadolinium-based contrast media depends on several factors and the occurrence of mild and severe adverse reactions with their use can be avoided.
Conclusions: for the use of gadolinium-based contrast media, the benefit/risk ratio should be assessed, this premise should coincide with the real need for an effective diagnosis and prognosis (or both). The objective is to administer the lowest possible dose, which is related to the maximum effective enhancement time.

Downloads

Download data is not yet available.

Author Biographies

José Luis Rodríguez Monteagudo, Clínica Central “Cira García”

Especialista de I y II Grado en Imagenología. Profesor Auxiliar en la Universidad de Ciencias Médicas de La Habana, Facultad de Medicina Finlay Albarrán. Investigador Agregado.

Anayda Alfonso Hidalgo, Universidad de Ciencias Médicas de La Habana, Facultad de Ciencias Médicas “Dr. Salvador Allende”

Especialista de I y II Grado en Farmacología. Máster en Educación Médica Superior. Profesora Auxiliar en Universidad de Ciencias Médicas de La Habana, Facultad Ciencias Médicas “Dr. Salvador Allende”. Investigadora Auxiliar.

References

1.Arias Gonzales M, Iglesias Castañón A, Ruibal Villanueva MC, Fernández Alonso D, Mañas Uxó J. Medios de contraste en RM. Guía práctica para el radiólogo [Internet]. Congreso SERAM 2012/S-0661. Granada: SERAM; 24-28/05/2012 [citado 11/03/2020]. Disponible en: https://epos.myesr.org/poster/esr/seram2012/S-0661. https://dx.doi.org/10.1594/seram2012/S-0661

2.Tsaid LL, Grant AK, Mortele KJ, Kung JW, Smith MP. A practical guide to RM Imaging Safety: What Radiologist need to know. Radiographics [Internet]. 2015 [citado 11/03/2020];35(6):1722-37. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26466181/. https://doi.org/10.1148/rg.2015150108

3.Valenzuela R, Arevalo O, Tavera A, Riascos R, Bonfante E, Patel R. Imágenes del depósito de gadolinio en el sistema nervioso central. Rev Chil Radiol [Internet]. 2017 [citado 11/03/2020];23(2):59-65. Disponible en: https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-93082017000200005. http://dx.doi.org/10.4067/S0717-93082017000200005

4.Madurga Sanz M. Agentes de contraste con gadolinio: recomendaciones y medidas adoptadas tras la revisión europea llevada a cabo sobre el riesgo de formación de depósitos tisulares (cerebro y otros). Panorama Actual Med [Internet]. 2018 [citado 11/03/2020];42(410):92-94. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=6342030

5.Buxton LO. Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination. En: Goodman and Gilman, editors. The pharmacological basis of therapeutics. 13th ed. Nueva York: McGraw-Hill Education; 2018. p. 13-30.

6.Valdizan E, Pazos A. Acciones de los fármacos I. Interacciones fármaco-receptor. En: Flórez J. Farmacología Humana. 6ta ed. Madrid: Elservier-MASSON; 2014. p. 7-15.

7.Armijo JA. Farmacocinética: absorción, distribución y eliminación de los fármacos. En: Flórez J. Farmacología Humana. 6ta ed. Madrid: Elservier-MASSON; 2014. p. 46-70.

8.Armijo JA. Farmacología clínica, individualización del tratamiento y monitorización de fármacos. En: Flórez J. Farmacología Humana. 6ta ed. Madrid: Elservier-MASSON; 2014. p. 83-105.

9.Rang HP. How drugs act: general principles. En: Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 8th ed. Londres: Churchill-Livingstone; 2015. p. 6-21.

10.Food & Drug Administration. La FDA advierte que los medios de contraste basados en gadolinio (MCBG) se depositan en el cuerpo y exige una nueva clase de advertencias [Internet]. Rockville: FDA; 2017 [citado 18/01/2020]. Disponible en: https://www.fda.gov/drugs/drug-safety-and-availability/la-fda-advierte-que-los-medios-de-contraste-basados-en-gadolinio-mcbg-se-depositan-en-el-cuerpo-y

11.Escribano F, Sentís M, Oliva JC, Tortajada L, Villajos M, Martín A, et al. Resonancia magnética dinámica de mama: estudio comparativo de gadobutrol y Gd-DTPA. Radiolog [Internet]. 2018 [citado 18/01/2020];60(1):49-56. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S003383381730187X. https://doi.org/10.1016/j.rx.2017.10.010

12.European Medicines Agency. Pharmacovigilance Risk Assessment Committee. Resumen general de la evaluación científica del PRAC [Internet]. Amsterdan: EMA; 2017 [citado 18/01/2020]. Disponible en: https://www.ema.europa.eu/en/documents/referral/gadolinium-article-31-referral-annex-ii_es.pdf

13.Martí Bonmatí L, Martí Bonmatí E. Retención de compuestos de gadolinio usados en resonancia magnética: revisión crítica y recomendaciones de las agencias regulatorias. Radiolog [Internet]. 2017 [citado 18/01/2020];59(6):469-477. Disponible en: https://www.elsevier.es/es-revista-radiologia-119-articulo-retencion-compuestos-gadolinio-usados-resonancia-S0033833817301522. https://doi.org/10.1016/j.rx.2017.09.007

14.Kalra MK, Sodickson AD, Mayo-Smith WW. CT Radiation: Key concepts for gentle and wise use. Radiographics [Internet]. 2015 [citado 18/01/2020];35(6):1706-1721. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26466180/. https://doi.org/10.1148/rg.2015150118

15.Salazar Cambronero R, Anguita Carpio C, Atauconcha Dorregaray GD. Seguridad en la administración de gadolinio en pruebas radiológicas. Metas Enferm [Internet]. 2015 [citado 18/01/2020];18(3):61-67. Disponible en: https://www.enfermeria21.com/revistas/metas/articulo/80733/seguridad-en-la-administracion-de-gadolinio-en-pruebas-radiologicas/

16.Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, et al. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol [Internet]. 2006 [citado 18/01/2020];41(3):213-221. Disponible en: https://pubmed.ncbi.nlm.nih.gov/16481903/. https://doi.org/10.1097/01.rli.0000197668.44926.f7

Downloads

Published

2023-03-29

How to Cite

1.
Rodríguez Monteagudo JL, Alfonso Hidalgo A. Contrasts in resonance: from linear to macrocyclic. Acta Méd Centro [Internet]. 2023 Mar. 29 [cited 2025 Jun. 27];17(2):374-81. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/1859

Issue

Vol. 17 No. 2 (2023): Abril-Junio

Section

Review Articles

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).